Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2008
Business Overview: Novavax is a clinical-stage pharmaceutical company focused on developing vaccines using proprietary virus-like-particle (VLP) technology. Key targets include H5N1 avian influenza, seasonal influenza, and Varicella Zoster. The company is transitioning away from its previous women's health product line (Estrasorb) to focus on vaccine development.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $458 | $461 |
| Net Loss | $(7,755) | $(8,388) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.14) |
| Cash and Cash Equivalents (End of Period) | $14,702 | $7,782 |
| Total Short-Term Investments | $26,191 | $N/A |
| Working Capital | $34,711 | $N/A |
| Total Debt (Convertible Notes + Notes Payable) | $22,193 | $N/A |
| Accumulated Deficit | $(207,482) | $(199,727) |
Note: Short-term investments include $14.6M in auction rate securities and $11.6M in held-to-maturity corporate bonds.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue remained flat ($458k vs $461k). However, product sales dropped to zero from $204k due to the discontinuation of Gynodiol sales. This was offset by a 90% increase in contract research and development revenue ($458k vs $241k), driven by NIH grants.
- Operating Expenses: Total operating expenses decreased 7% to $7.7M.
- R&D Expenses: Increased 21% to $4.4M due to expanded preclinical testing and manufacturing for influenza vaccine candidates.
- G&A Expenses: Decreased 29% to $3.2M, primarily due to a reduced adjustment to reserves for notes receivable from former directors ($0.2M increase in reserve vs $1.0M in prior year) and lower consulting fees.
- Discontinued Operations: Loss from discontinued operations (Philadelphia manufacturing facility) improved significantly, decreasing from $1.2M to $0.7M. This reflects the wind-down of Estrasorb production and termination of agreements with Allergan.
- Liquidity: Cash and cash equivalents increased by $10.4M to $14.7M, driven by a net increase in cash from investing activities ($15.6M) due to the maturity of short-term investments and an upfront payment from the Graceway transaction, partially offset by operating cash outflows.
Guidance, Outlook, and Risks
- Clinical Progress: Phase I/IIa enrollment for the H5N1 pandemic influenza vaccine began in March 2008. Initial immunogenicity and safety data are anticipated in Q3 2008, with study completion by year-end 2008.
- Graceway Transaction: In February 2008, Novavax sold Estrasorb assets (US, Canada, Mexico) to Graceway Pharmaceuticals. The company expects a net cash impact exceeding $2.5M in the first half of 2008 from this deal. Novavax will manufacture additional Estrasorb units for Graceway through July 2008 before closing the Philadelphia facility.
- Liquidity Outlook: Management believes current capital resources are adequate through Q1 2009. However, the company has an accumulated deficit of $207M and expects to continue incurring losses. Future funding may require new financings, licensing, or partnerships.
- Convertible Notes: $22.0M of 4.75% senior convertible notes are outstanding, maturing July 2009. The conversion price was lowered to $4.00 per share. Mandatory conversion is triggered if the stock price exceeds $7.00 for 15 of 30 consecutive trading days.
- Investment Risk: The company holds $14.6M in auction rate securities. While management believes these are not impaired, failed auctions could impact liquidity if the market does not recover.
Investor Verification Checklist
- Capital Runway: Verify if the $14.7M cash balance and $2.5M expected Graceway proceeds are sufficient to fund the H5N1 Phase I/IIa trial completion and GMP facility construction without dilutive equity raises.
- Auction Rate Securities: Assess the liquidity risk of the $14.6M holding in auction rate securities and the potential for impairment charges if auctions continue to fail.
- Convertible Note Conversion: Monitor the stock price relative to the $7.00 mandatory conversion trigger and the $4.00 conversion price to evaluate potential dilution.
- Graceway Deal Execution: Confirm the timing and receipt of the remaining payments from the Graceway asset sale and supply agreement.
- Related Party Notes: Review the status of the outstanding notes receivable from former directors ($1.2M reserve) and the likelihood of collection or further write-downs.